[{"orgOrder":0,"company":"University Hospital Ghent","sponsor":"Gedeon Richter | University Hospital Antwerp | AZ Jan Palfijn Gent | Our Lady of Lourdes Hospital Waregem","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"BELGIUM","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Inositol","moa":"Amyloid beta A4 protein (APP)","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"University Hospital Ghent","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital Ghent \/ Gedeon Richter | University Hospital Antwerp | AZ Jan Palfijn Gent | Our Lady of Lourdes Hospital Waregem","highestDevelopmentStatusID":"11","companyTruncated":"University Hospital Ghent \/ Gedeon Richter | University Hospital Antwerp | AZ Jan Palfijn Gent | Our Lady of Lourdes Hospital Waregem"},{"orgOrder":0,"company":"Lo.Li.Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Inositol","moa":"Amyloid beta A4 protein (APP)","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Lo.Li.Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lo.Li.Pharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Lo.Li.Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Lo.Li.Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"FRANCE","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Inositol","moa":"Amyloid beta A4 protein (APP)","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"Lo.Li.Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lo.Li.Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Lo.Li.Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Lo.Li.Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"FRANCE","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Inositol","moa":"Amyloid beta A4 protein (APP)","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"Lo.Li.Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lo.Li.Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Lo.Li.Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Inositol","moa":"Amyloid beta A4 protein (APP)","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ ZonMw","highestDevelopmentStatusID":"1","companyTruncated":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ ZonMw"},{"orgOrder":0,"company":"Lo.Li.Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Inositol","moa":"HCAR3\/NIACR1","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Lo.Li.Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lo.Li.Pharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Lo.Li.Pharma \/ Undisclosed"},{"orgOrder":0,"company":"BIOSYENT PHARMA INC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Inositol","moa":"||HCAR3\/NIACR1","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"BIOSYENT PHARMA INC","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BIOSYENT PHARMA INC \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BIOSYENT PHARMA INC \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for (-)-Inositol

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lo.Li.Pharma

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Lo.Li.Pharma

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Details : Myo-Inositol is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Polycystic Ovary Syndrome.

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          December 04, 2024

                          Lead Product(s) : Inositol

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Inofolic is a natural health product, combining myo-inositol and folic acid in a unique soft-gel capsule for women living with PCOS. Inofolic® helped 70% of women with PCOSii to regulate their menstrual cycles throughout the 16-week study period.

                          Product Name : Inofolic

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 08, 2023

                          Lead Product(s) : Inositol,Folic Acid

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Lo.Li.Pharma

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Lo.Li.Pharma

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Details : Inositol is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Metabolic Syndrome.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 19, 2023

                          Lead Product(s) : Inositol

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Lo.Li.Pharma

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Lo.Li.Pharma

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Details : Myo-Inositol is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Polycystic Ovary Syndrome.

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          January 10, 2023

                          Lead Product(s) : Inositol

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Details : Myo-Inositol is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Diabetes, Gestational.

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          September 01, 2022

                          Lead Product(s) : Inositol

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Undisclosed

                          Sponsor : ZonMw

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Lo.Li.Pharma

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Lo.Li.Pharma

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Details : Myo-Inositol is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Diabetes Mellitus, Type 2.

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          February 09, 2021

                          Lead Product(s) : Inositol

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          University Hospital Ghent

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          University Hospital Ghent

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Lead Product(s) : Inositol

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Study Phase : Phase IV

                          Sponsor : Gedeon Richter | University Hospital Antwerp | AZ Jan Palfijn Gent | Our Lady of Lourdes Hospital Waregem

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Myo-Inositol is a Dietary Supplement drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Ovulation Induction.

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          March 13, 2020

                          Lead Product(s) : Inositol

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Phase IV

                          Sponsor : Gedeon Richter | University Hospital Antwerp | AZ Jan Palfijn Gent | Our Lady of Lourdes Hospital Waregem

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank